NextCure, Inc. (NXTC) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$49.61M | -21.6% |
| 2024 | -$40.80M | +23.0% |
| 2023 | -$52.97M | +1.7% |
| 2022 | -$53.89M | +5.9% |
| 2021 | -$57.28M | -27.4% |
| 2020 | -$44.95M | -26.2% |
| 2019 | -$35.62M | -545.7% |
| 2018 | $7.99M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$49.61M | -21.6% |
| 2024 | -$40.80M | +23.0% |
| 2023 | -$52.97M | +1.7% |
| 2022 | -$53.89M | +5.9% |
| 2021 | -$57.28M | -27.4% |
| 2020 | -$44.95M | -26.2% |
| 2019 | -$35.62M | -545.7% |
| 2018 | $7.99M | — |